p51.SRE.mCMV.CD63-GFP.wpre
(Plasmid
#226773)
-
PurposeCD63-GFP in p52 (SRE backbone)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 226773 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneP53
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameCD63
-
Alt nameCD63-GFP
-
Entrez GeneCD63 (a.k.a. AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40, TSPAN30)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
p51.SRE.mCMV.CD63-GFP.wpre was a gift from Ferdinando Pucci (Addgene plasmid # 226773 ; http://n2t.net/addgene:226773 ; RRID:Addgene_226773) -
For your References section:
Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1+ T cells in the tumor microenvironment. Gonzalez-Callejo P, Guo Z, Ziglari T, Claudio NM, Nguyen KH, Oshimori N, Seras-Franzoso J, Pucci F. PLoS One. 2023 Feb 3;18(2):e0279400. doi: 10.1371/journal.pone.0279400. eCollection 2023. 10.1371/journal.pone.0279400 PubMed 36735677